Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia [11]

Leukemia

Volumn 19, Issue 9, 2005, Pages 1689-1692

  Roy, L ^a   Guilhot, J ^a   Martineau, G ^a   Larchee R ^a   Guilhot, F ^a,b  

^a Clinical Research Centre   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CARMUSTINE; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

BASAL CELL CARCINOMA; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN TUMOR; BREAST CANCER; CANCER INCIDENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON ADENOCARCINOMA; DIARRHEA; DRUG DOSE REGIMEN; EDEMA; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; KIDNEY CANCER; LETTER; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LONG TERM CARE; LYMPHADENOPATHY; MELANOMA; MOUTH TUMOR; MUSCLE CRAMP; NAUSEA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM HEMORRHAGE; SECOND CANCER; SKIN CARCINOMA; SKIN MANIFESTATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEM CELL TRANSPLANTATION; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER; UROTHELIUM; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; VOMITING; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PIPERAZINES; PYRIMIDINES;

EID: 26944433865     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403874     Document Type: Letter

References (13)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005; 105: 2640-2653.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Interferon and low-dose cytarabine compared with Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukaemia (CML-CP) treated with Imatinib (IM) therapy: Update from the IRIS study. Blood 2004; 104 (Suppl 1): 10a.
4. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.
5. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9: 271-281.
6. Remontet L, Estève J, Bouvier A-M, Grosclaude P, Launoy G, Menegoz F et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Santé Publique 2003; 51: 3-30.
7. Quaglia A, Parodi S, Grosclaude P, Martinez-Garcia C, Coebergh JW, Vercelli M. Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: An analysis of differential trends in incidence and mortality in France, Italy and pain. Eur J Cancer 2003; 39: 654-665.
8. Guilhot F, Abgrall JF, Harousseau JL, Bauters F, Brice P, Dine G et al. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): Preliminary cytogenetic results. Leuk Lymphoma 1993; 11: 181-183.
9. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F et al. Interferon alpha-2b combined with cytarabine vs interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-229.
10. Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J et al. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukaemia patients in chronic phase. Leukemia 2002; 16: 573-580.
11. Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann Intern Med 1999; 131: 738-744.
12. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
13. Hehlmann R, Berger U, Pfirrmann M, Hochaus A, Metzgeroth G, Maywald O et al. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukaemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea. Leukemia 2003; 17: 1529-1537.